ArticleAnalytical and bioanalytical chemistry2026
Determination of metabolites of the epoxy resin component bisphenol A diglycidyl ether (BADGE) in human urine using gas chromatography-tandem mass spectrometry.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bisphenol A diglycidyl ether (BADGE) is used as an epoxy resin component in numerous applications in industry and the consumer sector. Its use for inner coatings of food and beverage cans poses a source for BADGE exposure in the general population since migration of BADGE or its derivatives from coatings into food items takes place. The compound is currently under assessment as an endocrine disruptor and a potent skin sensitiser. Nevertheless, a reliable biomarker for estimating BADGE intake by humans has yet to be identified. The objective of the study was to develop and validate a human biomonitoring method that is suitable to detect BADGE exposure down to the concentration range of environmental background exposure. The analytical method presented here enables a sensitive and specific determination of the BADGE metabolites BAGE*H
Indexed as
Identifiers
42745030What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.